2:34 PM
 | 
Dec 22, 2017
 |  BioCentury  |  Finance

Less to gain

Why biotech stocks missed out on the tax reform rally in 4Q17

While most of the stock market partied in 4Q17 as the tax reform bill approached the goal line, biotech stocks have sulked in the corner.

Republicans turned their full attention to tax reform in late September and after a flurry of amendments and horse trading, the Tax Cuts and Jobs Act (H.R. 1) was signed into law by President Donald Trump on Friday.

As passage increasingly became a reality, market indexes continued to build momentum.

With one holiday-shortened week to go, the Dow Jones Industrial...

Read the full 401 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >